Dapitant. RPR 100893.
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D004558:Electric Stimulation; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D054833:Isoindoles; D008881:Migraine Disorders / Q000188:drug therapy*; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D012668:Trigeminal Ganglion / Q000187:drug effects / Q000502:physiology
D007211:Indoles; D054833:Isoindoles; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; C089835:RPR 100893